2. Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings

3. CARS

4. Responses From CART19 Treatment

5. Immunotherapy for Eradicating Residual Disease in Myeloma

6. Phase 1/2: HDACi as a Novel Strategy for Prevention of Acute GVHD

7. Allo-SCT in Patients Age > 70 y

8. Cord Colitis Syndrome

9. Impact of Mixed Chimerism

11. CD19-Targeted T Cells for Chemotherapy-Refractory ALL

12. MAC or RIC for Cord Blood Transplants

13. MAC or RIC for Cord Blood Transplants (cont)

14. Double- vs Single-Cord Transplants

15. CIBMTR Study: IV BU vs TBI-based MAC

16. Higher Dose BU RIC Regimen May Benefit a Subset of Patients

17. Administering IV BU to Achieve Optimum AUC

18. CLO/MEL as Conditioning Regimen

19. TLI-ATG Conditioning

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)

23. Abbreviations (cont)

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)